Shingles Vaccine Market by Product, Type, Distribution Channel

List of Tables

The Shingles Vaccine Market was valued at USD 1.73 billion in 2023, expected to reach USD 1.87 billion in 2024, and is projected to grow at a CAGR of 8.11%, to USD 2.99 billion by 2030.

The global shingles vaccine market is defined by its focus on the prevention of herpes zoster infections, particularly among individuals aged 50 and above. Shingles, caused by the reactivation of the varicella-zoster virus (chickenpox), necessitates vaccination to mitigate severe complications such as postherpetic neuralgia. The market is driven by an increasing aged population, rising awareness about the disease, and advancements in vaccine technology. Key applications include its use in elderly healthcare and immunocompromised patient management. End-user adoption spans across hospitals, clinics, and specialty healthcare centers. Growth factors include robust government initiatives, favorable reimbursement policies, and escalating healthcare expenditure. Opportunities arise from emerging markets with low vaccination rates, opportunities for enhanced vaccine strain targeting, and partnerships for innovative delivery methods. Current recommendations focus on expanding educational programs to boost uptake and employing targeted marketing strategies to reach high-risk demographics. However, limitations include high production costs, stringent regulatory hurdles, and public skepticism over vaccine safety that may hamper rapid market penetration. Additional challenges involve logistical issues in vaccine distribution, impact of vaccine hesitancy, and competition from existing pharmaceutical giants with entrenched healthcare products. Remarkable areas for innovation include research into long-lasting vaccine formulations, novel adjuvant systems to improve immune response, and mRNA-based vaccine technologies, which can offer faster production times and scalability. The strategic movement involves collaborative R&D and investment in genetically engineered vaccines that provide comprehensive coverage with minimal side effects. The market exhibits a competitive nature marked by the presence of major players like GlaxoSmithKline and Merck & Co., but it also presents a dynamic landscape with potential for new entrants who can leverage technological advancements, such as artificial intelligence for vaccine development, to carve out a niche in a growing sector.

KEY MARKET STATISTICS
Base Year [2023]	USD 1.73 billion
Estimated Year [2024]	USD 1.87 billion
Forecast Year [2030]	USD 2.99 billion
CAGR (%)	8.11%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Shingles Vaccine Market

The Shingles Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Increasing prevalence of chronic diseases
- Rising number of geriatric population worldwide
- Rising awareness about shingles health risks and growing focus on immunization
Market Restraints
- High capital requirements for vaccine development
Market Opportunities
- Ongoing Research & development initiatives on shingles vaccines
- Significantly increasing public health expenditure worldwide
Market Challenges
- Adverse effects associated with shingles vaccines

Porter's Five Forces: A Strategic Tool for Navigating the Shingles Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Shingles Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Shingles Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Shingles Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Shingles Vaccine Market

A detailed market share analysis in the Shingles Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Shingles Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Shingles Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Shingles Vaccine Market

A strategic analysis of the Shingles Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Shingles Vaccine Market, highlighting leading vendors and their innovative profiles. These include Astellas Pharma Inc., Barinthus Biotherapeutics plc, Bavarian Nordic, Biogenetech Co., Ltd., CanSino Biologics Inc., CSL Limited, Curevo Inc., Daiichi Sankyo Company, Limited, Dynavax Technologies Corporation, Emergent Biosolutions Inc., GeneOne Life Science, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., JCR Pharmaceuticals Co., Ltd., Jiangsu Recbio Technology Co., Ltd., Merck KGaA, Moderna, Inc., Pfizer Inc., Sanofi S.A., Sinovac Biotech Ltd., SK Chemicals, Takeda Pharmaceutical Company Limited, Valneva SE, and VBI Vaccines Inc..

Market Segmentation & Coverage

This research report categorizes the Shingles Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Product, market is studied across SkyZoster, Zostavax, and Shingrix.
Based on Type, market is studied across Live Attenuated Vaccine and Recombinant Vaccine.
Based on Distribution Channel, market is studied across Healthcare Centers and Pharmacies.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-563BF1FCEEC2

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Increasing prevalence of chronic diseases
  - 5.1.1.2. Rising number of geriatric population worldwide
  - 5.1.1.3. Rising awareness about shingles health risks and growing focus on immunization
- 5.1.2. Restraints
  - 5.1.2.1. High capital requirements for vaccine development
- 5.1.3. Opportunities
  - 5.1.3.1. Ongoing Research & development initiatives on shingles vaccines
  - 5.1.3.2. Significantly increasing public health expenditure worldwide
- 5.1.4. Challenges
  - 5.1.4.1. Adverse effects associated with shingles vaccines
5.2. Market Segmentation Analysis
- 5.2.1. Product: Rising significance of Shingrix for higher safety profile
- 5.2.2. Type: Understanding the benefits of recombinant shingles vaccines
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Shingles Vaccine Market, by Product

6.1. Introduction
6.2. SkyZoster
6.3. Zostavax
6.4. Shingrix

7. Shingles Vaccine Market, by Type

7.1. Introduction
7.2. Live Attenuated Vaccine
7.3. Recombinant Vaccine

8. Shingles Vaccine Market, by Distribution Channel

8.1. Introduction
8.2. Healthcare Centers
8.3. Pharmacies

9. Americas Shingles Vaccine Market

9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States

10. Asia-Pacific Shingles Vaccine Market

10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam

11. Europe, Middle East & Africa Shingles Vaccine Market

11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom

12. Competitive Landscape

12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
- 12.3.1. Dynavax Begins Clinical Trial for Promising Shingles Vaccine, Z-1018
- 12.3.2. Sinovac Biotech Ltd. Expands PROVARIX Vaccine Approval to Adolescents and Adults, Targeting Increased Public Health Benefits
- 12.3.3. GSK Expands Shingrix Vaccine Approval to Younger Adults in China, Targets Broader Public Health Impact
12.4. Strategy Analysis & Recommendation

Companies Mentioned

1. Astellas Pharma Inc.
2. Barinthus Biotherapeutics plc
3. Bavarian Nordic
4. Biogenetech Co., Ltd.
5. CanSino Biologics Inc.
6. CSL Limited
7. Curevo Inc.
8. Daiichi Sankyo Company, Limited
9. Dynavax Technologies Corporation
10. Emergent Biosolutions Inc.
11. GeneOne Life Science, Inc.
12. Gilead Sciences, Inc.
13. GlaxoSmithKline PLC
14. Inovio Pharmaceuticals, Inc.
15. JCR Pharmaceuticals Co., Ltd.
16. Jiangsu Recbio Technology Co., Ltd.
17. Merck KGaA
18. Moderna, Inc.
19. Pfizer Inc.
20. Sanofi S.A.
21. Sinovac Biotech Ltd.
22. SK Chemicals
23. Takeda Pharmaceutical Company Limited
24. Valneva SE
25. VBI Vaccines Inc.